5/13/2020 8:14:14 AM
BeyondSpring Granted New U.S. Patent For Plinabulin To Treat Severe Chemotherapy-Induced Neutropenia From Taxane
12/18/2019 7:08:20 AM
BeyondSpring Q3 Loss Per Share $0.65 Vs Loss Loss $0.37 Last Year
12/10/2019 8:11:56 AM
BeyondSpring Presents Study 106 Phase 3 Superior Trial Design Combining Plinabulin With Pegfilgrastim
12/27/2018 7:32:30 AM
BeyondSpring Unveils Positive Pre-NDA Meeting With The US FDA For Its Lead Asset, Plinabulin
10/23/2018 7:14:07 AM
BeyondSpring Announces Top Line Positive Efficacy And Safety Data From Phase 2 Study 106 With Lead Asset, Plinabulin
8/1/2018 7:15:20 AM
BeyondSpring Appoints Richard Daly As COO
6/21/2018 7:11:46 AM
BeyondSpring Q1 Net Loss $14.1 Mln Or $0.61 Per Share
5/30/2018 8:04:43 AM
BeyondSpring Raises Aggregate Gross Proceeds Of $20 Mln Through Registered Direct Offering
4/3/2018 7:16:15 AM
BeyondSpring 2017 Attributable Net Loss $91.8 Mln Vs. Loss $12.0 Mln Prior Year
3/27/2018 7:03:30 AM
BeyondSpring Appoints Edward Dongheng Liu As CFO
3/19/2018 8:09:43 AM
BeyondSpring Begins Phase 3 Clinical Development For Plinabulin For Prevention Of Chemotherapy-Induced Neutropenia